Akebia therapeutics, inc. (AKBA)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13
Revenues:
Total revenues

88,478

69,555

91,977

100,803

72,666

59,850

53,169

48,793

45,930

90,559

41,283

28,520

20,865

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Cost of goods sold:
Product

18,613

29,047

29,162

28,569

22,157

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of intangibles

9,100

9,100

9,101

9,100

9,100

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total cost of goods sold

27,713

38,147

38,263

37,669

31,257

7,768

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating expenses:
Research and development

81,231

80,412

74,512

85,694

82,351

87,052

70,634

71,917

61,404

68,382

58,711

43,751

60,049

33,435

31,238

30,877

20,235

14,243

15,604

6,505

6,664

4,932

6,648

5,525

6,158

1,311

3,240

2,453

1,897

Selling, general and administrative

37,983

44,918

34,178

36,068

34,291

55,121

10,378

12,538

9,024

7,567

6,748

6,905

5,788

6,144

4,944

5,311

5,811

5,807

4,074

4,384

4,232

5,675

2,936

2,315

3,751

4,890

794

667

678

License expense

676

969

929

895

736

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating expenses

119,890

126,299

109,619

122,657

117,378

142,240

81,012

84,455

70,428

75,949

65,459

50,656

65,837

39,579

36,182

36,188

26,046

20,050

19,678

10,889

10,896

10,607

9,584

7,840

9,909

6,201

4,034

3,120

2,576

Operating loss

-59,125

-94,891

-55,905

-59,523

-75,969

-90,158

-27,843

-35,662

-24,498

14,610

-24,176

-22,136

-44,972

-38,044

-36,182

-36,188

-26,046

-20,050

-19,678

-10,889

-10,896

-10,607

-9,584

-7,840

-9,909

-6,201

-4,034

-3,120

-2,576

Other income (expense):
Interest income (expense)

-1,972

-790

228

485

869

1,737

1,780

1,561

1,076

914

842

608

435

178

219

270

234

159

139

116

96

80

56

51

19

19

28

2

-754

Other income (expense)

350

-554

-185

23

-78

29

16

32

4

0

200

10

-6

4

-345

139

14

34

64

84

105

-

-

-

-

-

-

-

-

Net loss before income taxes

-60,747

-96,235

-55,862

-59,015

-75,178

-88,392

-26,047

-34,069

-23,418

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Benefit from income taxes

-

-1,752

-1,277

-845

-2,757

-28,338

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Extinguishment of debt and other liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

2,419

Reimbursements from Aerpio

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

180

171

193

-

238

287

290

Net loss

-60,747

-94,483

-54,585

-58,170

-72,421

-60,054

-26,047

-34,069

-23,418

15,524

-23,134

-21,518

-44,543

-37,862

-36,308

-35,779

-25,798

-19,857

-19,475

-10,689

-10,695

-10,371

-9,348

-7,618

-9,697

-5,947

-3,767

-2,830

-620

Accretion on preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-1

0

86,899

3,024

2,748

49,265

848

Net loss applicable to common stockholders - basic and diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-10,370

-9,348

-7,618

-96,597

-8,972

-6,516

-52,095

-1,469

Net loss per share - basic and diluted

-0.47

-0.79

-0.46

-0.49

-0.62

-0.87

-0.46

-0.60

-0.48

0.48

-0.49

-0.53

-1.15

-0.99

-0.96

-0.95

-0.70

-0.68

-0.68

-0.40

-0.53

36.19

-0.47

-0.39

-43.37

-8.74

-11.92

-103.19

-3.09

Weighted-average number of common shares - basic and diluted

128,395

119,358

118,863

118,268

117,063

69,404

57,027

56,890

48,613

47,485

46,938

40,819

38,759

38,285

37,897

37,811

36,873

30,447

28,784

26,614

20,030

20,055

19,691

19,652

2,227

648

546

504

475

Comprehensive loss:
Net loss and comprehensive loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-620

Net loss

-60,747

-94,483

-54,585

-58,170

-72,421

-60,054

-26,047

-34,069

-23,418

15,524

-23,134

-21,518

-44,543

-37,862

-36,308

-35,779

-25,798

-19,857

-19,475

-10,689

-10,695

-10,371

-9,348

-7,618

-9,697

-5,947

-3,767

-2,830

-620

Other comprehensive gain - unrealized gain on debt securities

-

-6

-17

59

225

148

50

91

-108

-219

73

-75

-179

-35

-44

63

-26

-227

20

-19

-8

-

-43

-8

-

-

-

-

-

Total comprehensive loss

-60,747

-94,489

-54,602

-58,111

-72,196

-59,906

-25,997

-33,978

-23,526

15,305

-23,061

-21,593

-44,722

-37,897

-36,352

-35,716

-25,824

-20,084

-19,455

-10,708

-10,703

-10,376

-9,391

-7,626

-9,697

-

-3,768

-2,830

-

Product Revenue, Net
Total revenues

29,200

28,915

30,004

29,089

23,100

6,824

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

License, Collaboration and Other Revenue
Total revenues

59,269

40,640

61,973

71,714

49,555

53,026

53,169

48,793

45,930

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-